NEJM: Tirzepatide's head-to-head Phase III study succeeded in reducing blood sugar and weight loss better than semaglutide

Glucagon-like peptide-1 (GLP-1) receptor agonist is an effective means for the treatment of type II diabetes , which has the effects of delaying gastric emptying, reducing appetite and reducing body weight

In this published, 40-week phase III trial, 1879 patients with type II diabetes, according to a ratio of 1:1:1:1, were randomized to receive Tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or a dose of 1.

At 40 weeks, the average change of glycosylated hemoglobin levels in the Tirzepatide 5 mg, 10 mg, and 15 mg groups from baseline were -2.

Differences in blood glucose-related endpoints between groups

The weight loss of patients in the Tirzepatide group was greater than that in the semaglutide group (the difference in weight changes in the 5 mg, 10 mg, and 15 mg groups were -1.

Difference in weight-related endpoints between groups

In the study, the most common adverse reactions were gastrointestinal reactions, mainly mild to moderate adverse events, including nausea, diarrhea and vomiting

Studies believe that for patients with type II diabetes, GLP-1R, GIPR dual agonist Tirzepatide is better than semaglutide in improving blood sugar and reducing body weight

Juan P.